The effects of iron oxide incorporation on the chondrogenic potential of three human cell types. (7th March 2012)

• Record Type: Journal Article
• Authors: Saha, Sushmita; Yang, Xuebin B.; Tanner, Steven; Curran, Stephen; Wood, David; Kirkham, Jennifer
• Is Part Of: Journal of tissue engineering and regenerative medicine. Volume 7:Number 6(2013:Jun.)
• Page Start: 461
• Page End: 469
• Publication Date: 2012-03-07
• Subjects: Tissue engineering -- Periodicals; Regeneration (Biology) -- Periodicals; 610.28
• DOI: 10.1002/term.544
• Languages: English
• ISSNs: 1932-6254

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <p> <bold>Non‐invasive monitoring of living cells <italic>in vivo</italic> provides an important tool in the development of cell‐based therapies in cartilage tissue engineering. High‐resolution magnetic resonance imaging (MRI) has been used to monitor target cell populations <italic>in vivo</italic>. However, the side‐effects on cell function of the labelling reagents, such as superparamagnetic iron oxide (SPIO), are still unclear. This study investigated the effect of SPIO particles on the chondrogenic differentiation of human bone marrow stromal cells (HBMSCs), neonatal and adult chondrocytes <italic>in vitro</italic>. Cells were labelled with SPIO for 24 h and chondrogenesis induced in serum‐free medium including TGF<italic>β</italic>3. For labelled/unlabelled cells, viability, morphology and proliferation were determined using CellTracker™ Green and PicoGreen dsDNA assays. The expression of <italic>SOX9</italic>, <italic>COL2A1</italic> and <italic>ACAN</italic> was investigated using qRT–PCR after 2, 7 and 14 days. The results showed that viability was unaffected in all of the cells but cell morphology changed towards a 'stretched' phenotype following SPIO uptake. Cell proliferation was reduced only for labelled neonatal chondrocytes. <italic>SOX9</italic> and <italic>COL2A1</italic> expression decreased at day 2 but not at days 7 and 14 for labelled HBMSCs and adult chondrocytes; <italic>ACAN</italic> expression was unaffected. In contrast, <italic>SOX9</italic> and <italic>COL2A1</italic> expression were unaffected in labelled neonatal chondrocytes but a decrease in <italic>ACAN</italic> expression was seen at day 14. The results suggest that downregulation of chondrogenic genes associated with SPIO labelling is temporary and target cell‐dependent. Resovist® can be used to label HBMSCs or mature chondrocytes for MR imaging of cells for cartilage tissue engineering. Copyright © 2012 John Wiley & Sons, Ltd.</bold> </p> </abstract>